日祥受邀參加第三屆海峽兩岸醫藥品研發合作研討會
本研討會係由大陸國家食品藥品監督管理總局(CFDA)及台灣行政院衛生署食品藥物管理局(TFDA)於「海峽兩岸醫藥衛生合作協議」架構下，雙方輪流舉行之醫藥品研發合作平台，本年度由TFDA主辦，台灣研發型生技新藥發展協會協辦，邀請兩岸醫藥品主管機關、學研界及產業界專家代表與會演講討論，以促進兩岸創新醫療產業合作交流，開展華人生技製藥經濟的蓬勃發展。
本屆研討會主題為「兩岸醫藥品管理制度改革進展，以及兩岸創新藥物研發合作展望」。將由兩岸學者、專家與醫藥企業菁英，介紹大陸44號公告下醫藥品法規改革方向，以及台灣醫藥法規最新發展，同時深入探討兩岸醫藥品臨床試驗審查(審批)、藥證持有人(許可人)制度的模式及趨勢，並展望台灣與大陸新藥新科技研發合作、產業生產佈局策略。
日祥榮幸受邀參與第三屆海峽兩岸醫藥品研發合作研討會，於研討會上發表「子宮頸癌甲基化新基因標記-兩岸臨床驗證經驗分享」之最新公司進展，更在會後與兩岸醫藥品學者、政府專家及廠商代表共同分享Cervi-M甲基化產品之研發、臨床研究，與相關法規經驗。
|
|
iStat Bomedical invited to the 3rd Cross-Strait drug research and development cooperation symposium |
This symposium is a pharmaceutical R&D cooperation platform held in turns by the Mainland China Food and Drug Administration (CFDA) and the Taiwan Executive Yuan Food and Drug Administration (TFDA) under the framework of the "Cross-Strait Medical and Health Cooperation Agreement". This year, sponsored by TFDA and co-organized by the Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), representatives and experts from the regulatory authorities, academic and industry from both sides of the Taiwan Strait are invited to give speeches and discussions to promote cross-strait cooperation and exchanges in the innovative medical industry, and to develop the Chinese biotechnology and pharmaceutical economy.
The theme of this symposium is "Progress in the reformation of the cross-strait pharmaceutical management system, and the prospect of cross-strait cooperation in innovative drug research and development". Scholars, experts and elites of pharmaceutical companies from both sides of the Taiwan Strait will introduce the direction of the reformation of pharmaceutical regulations under Mainland Announcement No. 44, as well as the latest development of Taiwan's pharmaceutical regulations.
iStat Biomedical was honored to be invited in this Symposium, where the company announced the latest company progress on "New methylation biomarker in cervical cancer - Cross-strait clinical validation experience sharing". Pharmaceutical scholars, government experts and manufacturer representatives from both sides of the Taiwan Strait shared their experience in the research and development, clinical research, and related regulations of Cervi-M methylated products.
About iStat Biomedical
iStat Biomedical is a Taiwan-based biotechnology company specialized in the development and manufacturing of gene methylation assay IVD products for the early detection of cancers. iStat Biomedical develops innovative products that are primarily used in the clinical laboratories, and provides physicians with alternative solutions for clinical managements. iStat Biomedical also provides services for gene methylation detection and IVD contract manufacturing.
iStat Biomedical Co., Ltd contact:
+886-2-26963518
本研討會係由大陸國家食品藥品監督管理總局(CFDA)及台灣行政院衛生署食品藥物管理局(TFDA)於「海峽兩岸醫藥衛生合作協議」架構下，雙方輪流舉行之醫藥品研發合作平台，本年度由TFDA主辦，台灣研發型生技新藥發展協會協辦，邀請兩岸醫藥品主管機關、學研界及產業界專家代表與會演講討論，以促進兩岸創新醫療產業合作交流，開展華人生技製藥經濟的蓬勃發展。
本屆研討會主題為「兩岸醫藥品管理制度改革進展，以及兩岸創新藥物研發合作展望」。將由兩岸學者、專家與醫藥企業菁英，介紹大陸44號公告下醫藥品法規改革方向，以及台灣醫藥法規最新發展，同時深入探討兩岸醫藥品臨床試驗審查(審批)、藥證持有人(許可人)制度的模式及趨勢，並展望台灣與大陸新藥新科技研發合作、產業生產佈局策略。
日祥榮幸受邀參與第三屆海峽兩岸醫藥品研發合作研討會，於研討會上發表「子宮頸癌甲基化新基因標記-兩岸臨床驗證經驗分享」之最新公司進展，更在會後與兩岸醫藥品學者、政府專家及廠商代表共同分享Cervi-M甲基化產品之研發、臨床研究，與相關法規經驗。
|
|
iStat Bomedical invited to the 3rd Cross-Strait drug research and development cooperation symposium |
This symposium is a pharmaceutical R&D cooperation platform held in turns by the Mainland China Food and Drug Administration (CFDA) and the Taiwan Executive Yuan Food and Drug Administration (TFDA) under the framework of the "Cross-Strait Medical and Health Cooperation Agreement". This year, sponsored by TFDA and co-organized by the Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), representatives and experts from the regulatory authorities, academic and industry from both sides of the Taiwan Strait are invited to give speeches and discussions to promote cross-strait cooperation and exchanges in the innovative medical industry, and to develop the Chinese biotechnology and pharmaceutical economy.
The theme of this symposium is "Progress in the reformation of the cross-strait pharmaceutical management system, and the prospect of cross-strait cooperation in innovative drug research and development". Scholars, experts and elites of pharmaceutical companies from both sides of the Taiwan Strait will introduce the direction of the reformation of pharmaceutical regulations under Mainland Announcement No. 44, as well as the latest development of Taiwan's pharmaceutical regulations.
iStat Biomedical was honored to be invited in this Symposium, where the company announced the latest company progress on "New methylation biomarker in cervical cancer - Cross-strait clinical validation experience sharing". Pharmaceutical scholars, government experts and manufacturer representatives from both sides of the Taiwan Strait shared their experience in the research and development, clinical research, and related regulations of Cervi-M methylated products.
About iStat Biomedical
iStat Biomedical is a Taiwan-based biotechnology company specialized in the development and manufacturing of gene methylation assay IVD products for the early detection of cancers. iStat Biomedical develops innovative products that are primarily used in the clinical laboratories, and provides physicians with alternative solutions for clinical managements. iStat Biomedical also provides services for gene methylation detection and IVD contract manufacturing.
iStat Biomedical Co., Ltd contact:
+886-2-26963518